Skip to main content

Table 5 Survival and toxicities of patients undergoing late course accelerated hyper-fractionated radiotherapy for esophageal squamous cell carcinoma

From: Elective lymph node irradiation late course accelerated hyper-fractionated radiotherapy plus concurrent cisplatin-based chemotherapy for esophageal squamous cell carcinoma: a phase II study

First author

Study

No. of patients

TNM stage

Treatment scheme

Overall survival

Locol control

Treatment failure

Toxicity (Grade≥3)

Shi XH [18]

Prospective

43

T1-4N0-1M0

41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid

5-year 34%

5-year 55%

LR 41.8% (18/43)

PI 27.9% (12/43)

DM 18.6% (8/43)

EI 34.9% (15/43)

Wang Y [19]

Prospective

52

T1-4N0-1M0

41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy,bid

1-year 80.0%

1-year 80.7%

LRF 13.5% (7/52)

PI 3.8% (2/52)

    

EI 9.6% (5/52)

 

3-year 41.2%

3-year 57.1%

DM 15.4% (8/52)

ES 1.9 % (1/52)

PF 0% (0/48)

    

EH 3.8% (2/52)

Zhao KL [20]

Retrospective

56

T1-2N0M0

41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid

1-year 90.9%

1-year 90.9%

LR 12.5% (7/56)

PI 5.4 % (3/56)

3-year 54.6%

3-year 84.5%

DM 21.4% (12/56)

EI 10.7 % (6/56)

ES 1.8 % (/56)

5-year 47.8 %

5-year 84.5 %

PF 1.8 % (/56)

Zhao KL [21]

Retrospective

201

T1-4N0-1M0

41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid

1-year 73%,

1-year 77%

LRF 38.4% (77/201)

EI 15.4% (31/201)

   

PI 7.0% (14/201)

3-year 34%,

3-year 58%

DM 34.9% (70/201)

EF 0.5% (1/201)

5-year 26%

5-year 56%

 

Zhao KL [22]

Prospective

54

T1-4N0-1M0

41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid Plus ≥2 cycles of CHT with cisplatin+5-FU

1-year 67%,

1-year 84%

LRF 25.9% (14/54)

EI 24.1% (13/54)

PI 5.5% (3/54)

3-year 44%,

3-year 74%

PF 14.8% (8/54)

5-year 40%

5-year 67%

DM 24% (13/54)

ES 3.7% (2/54)

Wang JH [23]

Prospective

48

T1-4N0-1M0

40Gy/20fx followed by 21–27 Gy/14-18fx with 1.5Gy, bid

1-year 79.2%

1-year 81.3%

LR 35.4% (17/48)

PI 33.33% (16/48)

EI 27.1% (13/48)

3-year 43.8%

3-year 50.0%

DM 16.7% (8/48)

ES 14.6% (7/48)

PF 0% (0/48)

  1. Note: distant metastasis–DM; local recurrence–LR; locoregional failure–LRF; esophagitis–EI; pneumonitis–PI; pulmonary fibrosis–PF; esophageal stenosis–ES; esophageal hemorrhage–EH; esophagus fistula–EF; fractions–fx; twice a day–bid; concurren chemotherapy–CHT.